{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:45:01Z","timestamp":1740167101723,"version":"3.37.3"},"reference-count":87,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T00:00:00Z","timestamp":1482192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Atrial fibrillation (AF) is associated with an increased risk of stroke compared with the general population. It is anticipated that by 2030 an estimated 14\u201317 million patients will be diagnosed with this most prevalent arrhythmia within the European Union. AF-related stroke confers a higher mortality and morbidity risk, and thus early detection and assessment for the initiation of effective stroke prevention with oral anticoagulation (OAC) is crucial. Recent guidelines point to the use of non-vitamin K antagonist OACs (NOACs) where appropriate in stroke prevention of patients with non-valvular AF. At present, there are four NOACS available, with no direct head-to-head comparisons to suggest the superiority of one drug over another.<\/ns4:p><ns4:p> Simple and practical risk assessment tools have evolved over the years to facilitate stroke and bleeding risk assessment in busy clinics and wards to aid decision-making. At present, the CHA<ns4:sub>2<\/ns4:sub>DS<ns4:sub>2<\/ns4:sub>VASc (congestive heart failure, hypertension, age 65\u201374\/&gt;75, diabetes mellitus, stroke\/transient ischemic attack\/thromboembolism, vascular disease, female sex) score is recommended by many international guidelines as a simple and practical method of assessing stroke risk in such patients. Alongside this, use of the HAS BLED (hypertension systolic blood pressure &gt;160 mmHg, abnormal liver\/renal function [with creatinine \u2265200 \u03bcmol\/L], stroke, bleeding history or predisposition, labile international normalized ratio [range &lt;60% of the time], elderly [&gt;65], concomitant drugs\/alcohol) score aims to identify patients at high risk of bleeding for more regular review and follow-up and draws attention to potentially reversible bleeding risk factors.<\/ns4:p><ns4:p> The aim of this review article is to provide an overview of recent advances in the understanding and management of AF with a focus on stroke prevention.<\/ns4:p>","DOI":"10.12688\/f1000research.10176.1","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T11:35:05Z","timestamp":1482233705000},"page":"2887","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention"],"prefix":"10.12688","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7635-5703","authenticated-orcid":false,"given":"Farhan","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Shantsila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2016,12,20]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"2289-304","DOI":"10.1253\/circj.CJ-12-1036","article-title":"Stroke and thromboembolism in atrial fibrillation.","volume":"76","author":"R Pisters","year":"2012","journal-title":"Circ J."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"276-86","DOI":"10.1160\/TH4-04-0383","article-title":"Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study.","volume":"112","author":"C Martinez","year":"2014","journal-title":"Thromb Haemost."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"857-67","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.","volume":"146","author":"R Hart","year":"2007","journal-title":"Ann Intern Med."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"933-42","DOI":"10.1160\/TH13-09-0734","article-title":"Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.","volume":"111","author":"G Lip","year":"2014","journal-title":"Thromb Haemost."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"2893-2962","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.","volume":"37","author":"P Kirchhof","year":"2016","journal-title":"Eur Heart J."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"826-34","DOI":"10.1160\/TH15-07-0565","article-title":"Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.","volume":"114","author":"G Lip","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"546-54","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review.","volume":"69","year":"2007","journal-title":"Neurology."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"1041-9","DOI":"10.1093\/eurheartj\/ehs435","article-title":"Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?","volume":"34","author":"G Lip","year":"2013","journal-title":"Eur Heart J."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"549-56","DOI":"10.1160\/TH13-12-1033","article-title":"Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project.","volume":"111","author":"A Banerjee","year":"2014","journal-title":"Thromb Haemost."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1165-9","DOI":"10.1160\/TH15-02-0154","article-title":"Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc \u22651, or higher?","volume":"113","author":"J Olesen","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1170-3","DOI":"10.1160\/TH15-03-0210","article-title":"The risks of risk scores for stroke risk assessment in atrial fibrillation.","volume":"113","author":"P Nielsen","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"943-59","DOI":"10.1016\/j.jacc.2015.06.1313","article-title":"Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications.","volume":"66","author":"M Dzeshka","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"606-15","DOI":"10.1161\/CIRCEP.109.910125","article-title":"Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation.","volume":"3","author":"M Allessie","year":"2010","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"996-1001","DOI":"10.1016\/j.amjcard.2012.12.005","article-title":"Left ventricular fibrosis in atrial fibrillation.","volume":"111","author":"E Shantsila","year":"2013","journal-title":"Am J Cardiol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"663-77","DOI":"10.1160\/TH15-07-0532","article-title":"Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature.","volume":"115","author":"M Di Minno","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"884-9","DOI":"10.1111\/ene.12400","article-title":"Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study.","volume":"21","author":"L Christensen","year":"2014","journal-title":"Eur J Neurol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"474-80","DOI":"10.1161\/CIRCEP.109.849638","article-title":"The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.","volume":"2","author":"T Glotzer","year":"2009","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"3697-706","DOI":"10.1161\/CIRCULATIONAHA.105.575332","article-title":"The G protein-gated potassium current IK,ACh is constitutively active in patients with chronic atrial fibrillation.","volume":"112","author":"D Dobrev","year":"2005","journal-title":"Circulation."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"861-8","DOI":"10.1161\/CIRCEP.114.001709","article-title":"Chronic atrial fibrillation increases microRNA-21 in human atrial myocytes decreasing L-type calcium current.","volume":"7","author":"A Barana","year":"2014","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"721-9","DOI":"10.1093\/eurheartj\/ehq464","article-title":"Abnormal calcium handling in atrial fibrillation is linked to up-regulation of adenosine A2A receptors.","volume":"32","author":"A Llach","year":"2011","journal-title":"Eur Heart J."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"4744-9","DOI":"10.1016\/j.ijcard.2013.07.234","article-title":"A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study.","volume":"168","author":"T Potpara","year":"2013","journal-title":"Int J Cardiol."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1167-76","DOI":"10.1160\/TH14-03-0231","article-title":"Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study.","volume":"111","author":"N Lowres","year":"2014","journal-title":"Thromb Haemost."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"377-87","DOI":"10.1016\/S1474-4422(15)70027-X","article-title":"Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis.","volume":"14","author":"L Sposato","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"iii-iv","DOI":"10.3310\/hta9400","article-title":"A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.","volume":"9","author":"F Hobbs","year":"2005","journal-title":"Health Technol Assess."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"2478-86","DOI":"10.1056\/NEJMoa1313600","article-title":"Cryptogenic stroke and underlying atrial fibrillation.","volume":"370","author":"T Sanna","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"2467-77","DOI":"10.1056\/NEJMoa1311376","article-title":"Atrial fibrillation in patients with cryptogenic stroke.","volume":"370","author":"D Gladstone","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"40-6","DOI":"10.1002\/clc.4960270111","article-title":"Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.","volume":"27","author":"C St\u00f6llberger","year":"2004","journal-title":"Clin Cardiol."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1112-6","DOI":"10.1016\/0002-9149(90)90323-S","article-title":"Risk for systemic embolization of atrial fibrillation without mitral stenosis.","volume":"65","author":"H Cabin","year":"1990","journal-title":"Am J Cardiol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"801-6","DOI":"10.1161\/01.STR.26.5.801","article-title":"Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group.","volume":"26","author":"J van Latum","year":"1995","journal-title":"Stroke."},{"key":"ref-30","first-page":"A20413","article-title":"Abstract 20413: Pattern of Atrial Fibrillation and the Risk of Ischemic Stroke - A Systematic Review and Meta-Analysis.","volume":"130","author":"M Lauw","year":"2014","journal-title":"Circulation."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"1591-602","DOI":"10.1093\/eurheartj\/ehw007","article-title":"The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis.","volume":"37","author":"A Ganesan","year":"2016","journal-title":"Eur Heart J."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"281-7a","DOI":"10.1093\/eurheartj\/ehu307","article-title":"Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.","volume":"36","author":"T Vanassche","year":"2015","journal-title":"Eur Heart J."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"288-96","DOI":"10.1093\/eurheartj\/ehu359","article-title":"Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.","volume":"36","author":"B Steinberg","year":"2015","journal-title":"Eur Heart J."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"2246-80","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS Guideline for the\u00a0Management of Patients With Atrial Fibrillation: Executive Summary : A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.","volume":"64","author":"C January","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1155-7","DOI":"10.1160\/TH14-11-0932","article-title":"Renal, endothelial function, warfarin management, and the CHADS2, CHA2DS2VASc and HAS-BLED scores inpredicting MACE in AF.","volume":"113","author":"A Blann","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1370-7","DOI":"10.1160\/TH14-10-0859","article-title":"Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula.","volume":"113","author":"V Sj\u00f6gren","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"781-2","DOI":"10.1160\/TH14-03-0228","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.","volume":"111","author":"S Husted","year":"2014","journal-title":"Thromb Haemost."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1160\/TH14-04-0325","article-title":"Comment on: editorial by Husted et al. \"Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel\". (Thromb Haemost 2014; 111: 781-782).","volume":"112","author":"J Ansell","year":"2014","journal-title":"Thromb Haemost."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"1139-51","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"S Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"883-91","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"M Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"981-92","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"C Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"2093-104","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"R Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"2325-32","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin.","volume":"128","author":"A Majeed","year":"2013","journal-title":"Circulation."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"2141-7","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.","volume":"63","author":"E Hylek","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"1873-80","DOI":"10.1093\/eurheartj\/ehu083","article-title":"Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.","volume":"35","author":"J Piccini","year":"2014","journal-title":"Eur Heart J."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1875-6","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial.","volume":"363","author":"S Connolly","year":"2010","journal-title":"N Engl J Med."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"660-7","DOI":"10.7326\/0003-4819-155-10-201111150-00004","article-title":"Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.","volume":"155","author":"J Oldgren","year":"2011","journal-title":"Ann Intern Med."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"1150-8","DOI":"10.1160\/TH16-06-0483","article-title":"Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses.","volume":"116","author":"W Darwiche","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"1277-89","DOI":"10.1160\/TH15-06-0497","article-title":"Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.","volume":"114","author":"J Seeger","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"975-86","DOI":"10.1160\/TH16-05-0403","article-title":"Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.","volume":"116","author":"G Lip","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"754-63","DOI":"10.1160\/TH16-03-0203","article-title":"Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.","volume":"116","author":"J Carmo","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"429-35","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.05.007","article-title":"Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.","volume":"21","author":"J Eikelboom","year":"2012","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"1749-58","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.","volume":"380","author":"R Lopes","year":"2012","journal-title":"Lancet."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"348-353.e1","DOI":"10.1016\/j.ahj.2009.08.026","article-title":"Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.","volume":"159","author":"J Eikelboom","year":"2010","journal-title":"Am Heart J."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"806-17","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation.","volume":"364","author":"S Connolly","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"25-30","DOI":"10.1016\/j.ahj.2014.09.006","article-title":"Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.","volume":"169","author":"C Granger","year":"2015","journal-title":"Am Heart J."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"31-9","DOI":"10.1160\/TH15-04-0350","article-title":"Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.","volume":"115","author":"C Martinez","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"S13-S23","DOI":"10.1160\/TH16-06-0485","article-title":"Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice.","volume":"116","author":"J Beyer-Westendorf","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"939-49","DOI":"10.1160\/TH15-10-0840","article-title":"Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.","volume":"115","author":"J Hecker","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"403-9","DOI":"10.1160\/TH15-05-0383","article-title":"Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.","volume":"114","author":"A Blann","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"1162-3","DOI":"10.1160\/TH15-04-0324","article-title":"Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects.","volume":"113","author":"E Hobl","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"511-20","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran Reversal.","volume":"373","author":"C Pollack","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"943-51","DOI":"10.1160\/TH14-12-1080","article-title":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.","volume":"113","author":"S Glund","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"198-205","DOI":"10.1160\/TH15-03-0192","article-title":"Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.","volume":"114","author":"C Pollack","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"931-42","DOI":"10.1160\/TH14-11-0982","article-title":"Reversal of anticoagulants: an overview of current developments.","volume":"113","author":"A Greinacher","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-66","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban.","author":"J Ansell","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"381-3","DOI":"10.1160\/TH14-01-0063","article-title":"Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation.","volume":"111","author":"D Lane","year":"2014","journal-title":"Thromb Haemost."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"1747-69","DOI":"10.1093\/europace\/euv233","article-title":"Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE).","volume":"17","author":"D Lane","year":"2015","journal-title":"Europace."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"955-62","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"C Ruff","year":"2014","journal-title":"Lancet."},{"year":"2014","key":"ref-70","article-title":"Atrial Fibrillation: management"},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"587-9","DOI":"10.1160\/TH16-08-0658","article-title":"\"Unreal world\" or \"real world\" data in oral anticoagulant treatment of atrial fibrillation.","volume":"116","author":"B Freedman","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"1093-8","DOI":"10.1160\/TH15-10-0825","article-title":"Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation.","volume":"114","author":"T Potpara","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"1290-8","DOI":"10.1160\/TH15-06-0453","article-title":"A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.","volume":"114","author":"T Villines","year":"2015","journal-title":"Thromb Haemost."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"152-60","DOI":"10.1160\/TH15-03-0247","article-title":"Dabigatran use in elderly patients with atrial fibrillation.","volume":"115","author":"M Avgil-Tsadok","year":"2016","journal-title":"Thromb Haemost."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"1145-53","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.","volume":"37","author":"A Camm","year":"2016","journal-title":"Eur Heart J."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"2047-53","DOI":"10.1080\/03007995.2016.1237937","article-title":"Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.","volume":"32","author":"C Coleman","year":"2016","journal-title":"Curr Med Res Opin."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"2882-2889","DOI":"10.1093\/eurheartj\/ehw233","article-title":"Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.","volume":"37","author":"J Bassand","year":"2016","journal-title":"Eur Heart J."},{"key":"ref-78","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-016-0189-9","article-title":"Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.","author":"I Hernandez","year":"2016","journal-title":"Am J Cardiovasc Drugs."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"752-63","DOI":"10.1111\/ijcp.12863","article-title":"Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a \"real-world\" observational study in the United States.","volume":"70","author":"G Lip","year":"2016","journal-title":"Int J Clin Pract."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"534-42","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.","volume":"374","author":"D Holmes","year":"2009","journal-title":"Lancet."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"1-12","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.","volume":"64","author":"D Holmes","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"2614-23","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis.","volume":"65","author":"D Holmes","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"1790-8","DOI":"10.1016\/j.jacc.2013.01.061","article-title":"Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation.","volume":"61","author":"O Alli","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"1925-32","DOI":"10.1016\/j.jcin.2015.08.035","article-title":"Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience.","volume":"8","author":"M Price","year":"2015","journal-title":"JACC Cardiovasc Interv."},{"key":"ref-85","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw048","article-title":"Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation.","author":"S Panikker","year":"2016","journal-title":"Eur Heart J."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"1170-9","DOI":"10.4244\/EIJY15M01_06","article-title":"Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug.","volume":"11","author":"A Tzikas","year":"2016","journal-title":"EuroIntervention."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"1030-6","DOI":"10.1016\/j.hrthm.2016.01.022","article-title":"Short and long-term outcomes of percutaneous left atrial appendage suture ligation: Results from a US multicenter evaluation.","volume":"13","author":"D Lakkireddy","year":"2016","journal-title":"Heart Rhythm."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-2887\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-2887\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-2887\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T11:26:33Z","timestamp":1553253993000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-2887\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,20]]},"references-count":87,"URL":"https:\/\/doi.org\/10.12688\/f1000research.10176.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.10962.r18637","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.10962.r18640","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.10962.r18632","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"type":"electronic","value":"2046-1402"}],"subject":[],"published":{"date-parts":[[2016,12,20]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-2887\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.10962.r18640, David R. Holmes, Mayo Clinic, Rochester, MN, USA, 20 Dec 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2887\/v1#referee-response-18640","order":0,"name":"referee-response-18640","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.10962.r18632, John Zafiris, George Papanikolaou General Hospital, Thessaloniki, Greece, 20 Dec 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2887\/v1#referee-response-18632","order":1,"name":"referee-response-18632","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.10962.r18637, Victor Serebrauny, Johns Hopkins University, Baltimore, MD, USA, 20 Dec 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2887\/v1#referee-response-18637","order":2,"name":"referee-response-18637","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}